ENT-001 is under clinical development by Enthera and currently in Phase I for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase I drugs for Type 1 Diabetes (Juvenile Diabetes) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ENT-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ENT-001 overview

ENT-001 is under development for the treatment of type 1 diabetes and Ulcerative Colitis. The drug candidate is a recombinant protein containing ecto-TMEM219 adminstered through intravenous route. It acts by binding to insulin like growth factor binding protein 3 (IGFBP3).

Enthera overview

Enthera, a subsidiary of BiovelocITA Srl, is a biotechnology company, which strives to discover novel medicines for the treatment of diabetes and related gastrointestinal disorders. The company’s major pipeline products include IGFBP3/TMEM219 inhibitors to treat Type 1 Diabetes (T1D) and autoimmune inflammatory diseases such as Inflammatory Bowel Disease (IBD). It’s therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases. The company established a portfolio of strategic collaborations with leading academic centers of excellence, including the San Raffaele Hospital and the University of Milan. Enthera is headquartered in Milano, Lombardia, Italy.

For a complete picture of ENT-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.